Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

A study in Ecuador reveals the rapid emergence of SARS-CoV-2 variants, highlighting the importance of strengthening genomic ...

New findings from the National Institutes of Health’s (NIH) Researching COVID to Enhance Recovery (RECOVER(link is external)) ...

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as sus ...